Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9511570 | 0.92 | TSHR (0.56) | THRBTSHRPOLBAPEX1HTT | |
| SCHEMBL9514375 | 0.92 | TSHR (0.61) | THRBTSHRPOLBAPEX1HTT | |
| Methacrylic Acid SCHEMBL9269881 | 0.87 | THRB (0.65) | THRBTSHRPOLBAPEX1HTT | |
| Methacrylic Acid SCHEMBL11497673 | 0.87 | THRB (0.65) | THRBTSHRPOLBAPEX1HTT | |
| SCHEMBL2067041 | 0.85 | THRB (0.63) | THRBTSHRPOLBAPEX1HTT | |
| Methacrylic Acid SCHEMBL22325481 | 0.85 | THRB (0.63) | THRBTSHRPOLBAPEX1HTT | |
| SCHEMBL15636 | 0.84 | THRB (0.74) | THRBTSHRPOLBAPEX1HTT | |
| SCHEMBL6142874 | 0.84 | THRB (0.74) | THRBTSHRPOLBAPEX1HTT | |
| SCHEMBL5675198 | 0.83 | THRB (0.61) | THRBTSHRPOLBAPEX1HTT | |
| Benzene SCHEMBL28145673 | 0.82 | THRB (0.65) | THRBTSHRPOLBAPEX1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10004673-B1 | Hair treatment composition comprising Michael addition product and methods for treating hair | L'OREAL (FR) | 2018-06-26 | — | — | US | claimed |
| EP-0325038-B1 | Surface priming composition for proteinaceous substrates, method of making and using same | OPI PROD INC (US) | 1993-11-03 | — | — | EP | claimed |
| US-4913939-A | Reaction product of cyclic anhydride and hydroxy compound; adhesion of adhesives | REM SYSTEMS, INC. (US) | 1990-04-03 | — | — | US | claimed |
| US-4863993-A | Surface priming composition for proteinaceous substrates; method of making and using same | OPI PRODUCTS, INC. (US) | 1989-09-05 | — | — | US | claimed |
| EP-0325038-A2 | Surface priming composition for proteinaceous substrates, method of making and using same | OPI PRODUCTS, INC. (US) | 1989-07-26 | — | — | EP | claimed |
| US-10004673-B1 | Hair treatment composition comprising Michael addition product and methods for treating hair | L'OREAL (FR) | 2018-06-26 | — | — | US | disclosed |
| US-4913939-A | Reaction product of cyclic anhydride and hydroxy compound; adhesion of adhesives | REM SYSTEMS, INC. (US) | 1990-04-03 | — | — | US | disclosed |
| US-4863993-A | Surface priming composition for proteinaceous substrates; method of making and using same | OPI PRODUCTS, INC. (US) | 1989-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10004673-B1 | Hair treatment composition comprising Michael addition product and methods for treating hair | SRM, CRAT, C9 | THRB 1763/4885TSHR 1844/4885POLB 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.